Home > Protocol Summaries: Compounds > GSK1521498

Protocol Summaries: GSK1521498

Protocol Summaries for GSK1521498
GSK
Study ID		 Phase Title Status
111314 Phase 1 A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects Completed
111848 Phase 1 An open-label, non-randomized [11C]carfentanil PET study in healthy male subjects to investigate brain mu-opioid receptor occupancy, pharmacokinetics, and pharmacodynamics of single oral doses of GSK1521498 and naltrexone. Completed
111849 Phase 1 A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of 10 days of repeat dosing of GSK1521498 in overweight or obese but otherwise healthy subjects. Completed

Filter list by: